The antibody response after primary vaccination and annual revaccination with a multivalent DAPPi-L vaccine was assessed respectively in SPF dogs and in client owned dogs against the Grippotyphosa (Lg), Canicola (Lc) and Icterohaemorrhagiae (Li) Leptospira serovars. To overcome limitations of the microscopic agglutination test (MAT), we developed serovar-specific and sensitive blocking ELISA assays. Serovar-specific antibodies against Lg, Lc and Li were detected in 100%, 45% and 91% of dogs, respectively, after the first dose of vaccine, and in 100% of dogs for all serovars after the second dose. In addition, mean ELISA antibody titers increased 14 days after annual revaccination with most dogs remaining ELISA antibody positive against Lg (85.3%), Lc (90%) and Li (100%). Parallel testing of sera from the annual revaccination study in the MAT and ELISA assays resulted in an overall agreement of 72%, 67%, 77% of samples for Lg, Lc and Li serovars, respectively. More sera tested positive by ELISA than by MAT, suggesting that the ELISA assay is more sensitive than the MAT. These three new antibody-based assays are the first suitable and reliable ELISA assays for the assessment of the canine antibody response following vaccination and an attractive alternative to the MAT.

中文翻译：

---

特异于钩端螺旋体血清型Grippotyphosa，Canicola和Icterohaemorrhagiae抗体ELISA的开发，以监测疫苗的免疫原性。

分别在SPF犬和客户拥有的犬中评估了多价DAPPi-L疫苗的初次疫苗接种和年度再疫苗接种后的抗体反应，以防灰痢（Lg），Canicola（Lc）和Icterohaemorrhagiae（Li）钩端螺旋体血清型。为了克服显微镜凝集试验（MAT）的局限性，我们开发了血清特异性和敏感的封闭ELISA分析。第一次接种疫苗后，分别在100％，45％和91％的狗中检出了针对Lg，Lc和Li的血清型特异性抗体，而在第二次接种后，所有血清型的狗中均检出了100％的狗。此外，每年重新接种后14天，平均ELISA抗体滴度增加，大多数狗对Lg（85.3％），Lc（90％）和Li（100％）的ELISA抗体均为阳性。在MAT和ELISA分析中，通过年度再免疫研究对血清进行并行测试，分别得出Lg，Lc和Li血清型抗体的总体一致性分别为72％，67％和77％。ELISA检测出的血清比MAT检测出的血清阳性，表明ELISA检测比MAT更为灵敏。这三种新的基于抗体的检测方法是用于评估疫苗接种后犬抗体反应的首个合适且可靠的ELISA检测方法，是MAT的替代方法。